AX-2025-020535
Melanotan II · 10 mg declared · Shanghai Sigma-Audley New Material Technology Co., Ltd. · lot SSA-2501-N6217
- Report ID
- AX-2025-020535
- Compound
- Melanotan II
- Compound class
- Melanocortin-receptor peptides
- Supplier
- SSA — Shanghai Sigma-Audley New Material Technology Co., Ltd.
- Batch / lot
- SSA-2501-N6217
- Declared label claim
- 10mg
- Laboratory
- Janoshik Analytical
- Assay date
- 13 Mar 2025
- Submitted
- 14 Mar 2025
- Quarter
- 2025-Q1
- Submitter
- i.nwosu
- Sample provenance
- Supplier-supplied
Results
Measured against the index acceptance specification for the melanocortin-receptor peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.
| Parameter | Method | Result | Unit | Index spec | |
|---|---|---|---|---|---|
| Purity | RP-HPLC, 30 min gradient, 214 nm | 98.73 | % area | ≥ 98.5 | PASS |
| Total impurities | RP-HPLC, sum of reported peaks | 1.27 | % area | ≤ 1.5 | PASS |
| Largest single impurity | RP-HPLC — oxidised Trp (+16 Da) | 0.84 | % area | ≤ 1.00 | PASS |
| Identity | not ordered on this submission | not determined | — | required for VERIFIED status | NOT TESTED |
| Total peptide content | by difference from the gravimetric mass balance | 90.10 | %w/w | — | NOT TESTED |
| Target-compound content | total peptide content × purity | 88.96 | %w/w | — | NOT TESTED |
| Gross fill (as weighed) | five-place balance, under nitrogen | 10.37 | mg | 10 mg declared | NOT TESTED |
| Recovered target peptide | gross fill × target content | 9.225 | mg | 10 mg claim | NOT TESTED |
| Recovery against label claim | recovered ÷ claim | 92.3 | % | 90.0 – 110.0 | PASS |
| Water content | Karl Fischer, coulometric, duplicate | 5.06 | % | ≤ 8.0 | PASS |
| Counter-ion (acetate) | anion-exchange ion chromatography | 4.10 | % | ≤ 10.0 | PASS |
| Residual solvent + inorganic residue | estimated — see /methods/residual-solvents-q3c/ | 0.74 | % | — | NOT TESTED |
| Endotoxin | not ordered on this submission | not determined | — | ≤ 5.0 | NOT TESTED |
| Sterility | not ordered on this submission | not determined | — | no growth | NOT TESTED |
| Appearance | visual, diffuse light, black and white background | Off-white lyophilised cake, intact | — | white to off-white intact cake | PASS |
| Reconstitution clarity | reconstituted per submitter procedure | Clear, colourless, no visible particulates | — | clear, no visible particulates | PASS |
| pH (reconstituted, 1 mg/mL) | potentiometric, two-point calibration | 5.18 | — | 2.5 – 8.0 | PASS |
| Retention time (observed) | RP-HPLC, 30 min gradient | 9.79 | min | 9.84 ± 0.25 (normalised) | PASS |
| Peak asymmetry (10 % height) | Ph. Eur. 2.2.46 | 0.88 | — | 0.80 – 1.50 | PASS |
| Plate count, main peak | N = 5.54 (t/w½)² | 48,096 | — | ≥ 20,000 | PASS |
| Resolution to nearest impurity | vs [L-Phe7]-diastereomer | 0.87 | — | no index criterion | REPORTED |
Chromatogram and peak integration
The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.
| # | Peak | RT | Area (µV·s) | % area | Δ mass (Da) |
|---|---|---|---|---|---|
| 1 | Melanotan II — main peak | 9.79 | 4,798,584 | 98.73 | — |
| 2 | oxidised Trp (+16 Da) | 9.43 | 40,827 | 0.84 | +15.995 |
| 3 | [L-Phe7]-diastereomer | 9.63 | 10,207 | 0.21 | 0.000 |
| 4 | MT-II dimer (head-to-tail) | 12.14 | 5,832 | 0.12 | +1023.540 |
| 5 | des-acetyl MT-II (−42 Da) | 9.31 | 2,430 | 0.05 | -42.011 |
| 6 | linear (open-lactam) precursor (+18 Da) | 9.05 | 2,430 | 0.05 | +18.011 |
| Closure check — purity + Σ impurities | 100.00 | CLOSES | |||
Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.
Gravimetric mass balance
Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.
| Component | Determination | %w/w of cake |
|---|---|---|
| Water | Karl Fischer | 5.06 |
| Counter-ion (acetate) | ion chromatography | 4.10 |
| Residual solvent + inorganic residue | estimated | 0.74 |
| Total peptide content | by difference | 90.10 |
| Total | 100.00 CLOSES | |
Supplier certificate, as declared
The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.
| Figure | Supplier COA | This report | Index note |
|---|---|---|---|
| Purity (% area) | 99.37 | 98.73 | divergence +0.78 pp vs batch median |
| Total impurities (% area) | 0.63 | 1.27 | |
| Largest single impurity (% area) | not stated | 0.84 | |
| Water (%) | 4.5 | 5.06 | |
| Counter-ion (%) | not stated | 4.10 | |
| Peptide content (%w/w) | 90.7 | 90.10 | |
| Endotoxin (EU/mg) | not stated | not determined | |
| Method stated on certificate | YES | — | column, gradient and wavelength given |
Provenance and caveats
Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.
- Sample provenance
- Supplier-supplied
- Evidentiary weight
- Weaker evidence. Read with the caveat below.
- Chain of custody
- Supplier despatch → laboratory direct (courier, cold pack, 3 d) → assay. Submitter did not handle the vial.
- Assay date
- 13 Mar 2025
- Submitted to the index
- 14 Mar 2025
- Laboratory
- Janoshik Analytical, Ostrava, Czechia
- Method basis
- 30 min gradient · high-resolution MS
- Verification status
- PURITY ONLY
Annotations
No annotations on this record. Annotations are short signed technical comments from index contributors; see how to contribute.
Related records
Same batch — lot SSA-2501-N6217 n=6
| Report | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|
| AX-2025-020531 | SSA-2501-N6217 | VendorInvestigate | 2025-Q1 | 98.37 | 5.64 | 91.4 | Buyer-sourced | 1 | FAIL |
| AX-2025-020532 | SSA-2501-N6217 | Janoshik | 2025-Q1 | 99.46 | 5.34 | 94.2 | Supplier-supplied | 1 | MARGINAL |
| AX-2025-020533 | SSA-2501-N6217 | Janoshik | 2025-Q1 | 98.44 | 5.26 | — | Buyer-sourced | 1 | FAIL |
| AX-2025-020534 | SSA-2501-N6217 | Janoshik | 2025-Q1 | 99.11 | 5.31 | 93.2 | Supplier-supplied | 1 | MARGINAL |
| AX-2025-020536 | SSA-2501-N6217 | Medutest | 2025-Q1 | 98.24 | 4.82 | — | Supplier-supplied | 1 | FAIL |
Cross-sections
| Report | Supplier | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|
| AX-2026-042648 | GGPeps | GGPE-2603-P8735 | Janoshik | 2026-Q3 | 99.10 | 6.97 | — | Supplier-supplied | 4 | MARGINAL |
| AX-2026-042479 | SWB | SWB-2603-A5707 | Janoshik | 2026-Q3 | 99.16 | 3.67 | 94.5 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-042481 | SWB | SWB-2603-A5707 | Medutest | 2026-Q3 | 98.95 | 3.37 | 90.8 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-042650 | GGPeps | GGPE-2603-P8735 | Medutest | 2026-Q3 | 99.86 | 6.49 | — | Supplier-supplied | 3 | MARGINAL |
| AX-2026-042483 | SWB | SWB-2603-A5707 | Janoshik | 2026-Q3 | 99.38 | 3.73 | 107.2 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-042651 | GGPeps | GGPE-2603-P8735 | PeptideMeter | 2026-Q3 | 99.53 | 7.04 | 90.7 | Supplier-supplied | 4 | MARGINAL |
| AX-2026-042478 | SWB | SWB-2603-A5707 | VendorInvestigate | 2026-Q3 | 98.73 | 4.34 | — | Buyer-sourced | 1 | MARGINAL |
| AX-2026-042482 | SWB | SWB-2603-A5707 | Janoshik | 2026-Q3 | 99.22 | 4.66 | — | Supplier-supplied | 1 | MARGINAL |
| Report | Compound | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|
| AX-2026-043144 | GHK-Cu | SSA-2604-V7620 | Janoshik | 2026-Q2 | 98.35 | 5.25 | 105.8 | Supplier-supplied | 0 | PASS |
| AX-2026-043141 | Semax | SSA-2604-L7628 | Kestrel | 2026-Q2 | 98.84 | 8.58 | 93.2 | Supplier-supplied | 2 | MARGINAL |
| AX-2026-043117 | Mazdutide | SSA-2605-G6781 | Janoshik | 2026-Q2 | 99.23 | 3.67 | 90.4 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-043136 | BPC-157 | SSA-2601-N6752 | Janoshik | 2026-Q2 | 97.75 | 4.32 | — | Supplier-supplied | 2 | FAIL |
| AX-2026-043118 | Mazdutide | SSA-2605-G6781 | Medutest | 2026-Q2 | 98.29 | 2.65 | 88.7 | Buyer-sourced | 2 | MARGINAL |
| AX-2026-043138 | BPC-157 | SSA-2601-N6752 | Janoshik | 2026-Q2 | 98.00 | 4.30 | 101.0 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-043137 | BPC-157 | SSA-2601-N6752 | Janoshik | 2026-Q2 | 97.41 | 4.36 | 104.5 | Laboratory-retained | 1 | FAIL |
| AX-2026-043146 | Enclomiphene citrate | SSA-2603-C6950 | Medutest | 2026-Q2 | 97.92 | 3.11 | 92.9 | Buyer-sourced | 2 | FAIL |